11 Jul CellProthera and BioCardia Collaborate on Phase 2 Trial of ProtheraCytes to Treat AMI
July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative phase 2 trial of CellProthera’s ProtheraCytes for the treatment of acute myocardial infarction (AMI). Additionally, the companies noted they plan to continue the collaboration into phase 3.
Cardiac Interventions TODAY | July 8, 2024